The issue of reactivating hepatitis B and other chronic viruses such as herpes zoster after treatment for myeloproliferative neoplasms (MPN) is an emerging issue in hematologic malignancies, due to the power of newer therapies.
A recent retrospective analysis assessed the incidence of hepatitis B virus (HBV) reactivation among patients with myeloproliferative neoplasms (MPN) during and after treatment with ruxolitinib.
The issue of reactivation of HBV and other chronic viruses such as herpes zoster is an emerging issue in hematologic malignancies, due to the potency of the improved therapies. In general, the risk of HBV reactivation is different in patients with chronic HBV and resolved HBV.
Anti-CD20 monoclonal antibodies and ibrutinib have been linked with an increased risk of HBV reactivation in patients with previous infections, the authors noted. Ruxolitinib, a Janus kinase (JAK) inhibitor, weakens dendritic cell and T-cell functions, lowering cytokine production, which results in impaired control of silent infections and an increased risk of virus reactivation.
In prior trials, a few patients were reported to experience HBV reactivation after ruxolitinib, but the actual incidence of HBV reactivation in patients with MPN and chronic or resolved HBV infection during and after ruxolitinib treatment remains unclear.
This study was conducted in China; 224 patients with MPN were treated using ruxolitinib between February 2013 and February 2020.
Of the 224, 162 were excluded for being negative to all tests for HBV or for being positive for HBsAb only.
Of the 62 patients with resolved or chronic HBV treated with ruxolitinib, 58.1% were male, with a median age of 53.5. A little more than half had primary myelofibrosis; the remaining had various types of essential thrombocythemia or polycythemia vera.
Of 62 patients, 6 had chronic HBV, and 56 had resolved HBV infection. Of the 56 who had resolved infection, 43 patients had received combination treatment with thalidomide, prednisone, and stanozolol (TSP) during ruxolitinib treatment.
Of the 6 with chronic HBV, 2 did not take any antiviral prophylaxis and subsequently developed HBV reactivation and a flare of hepatitis.
The other 4 patients with chronic HBV infection did receive antiviral prophylaxis therapy before treatment with ruxolitinib did not develop HBV reactivation.
Of patients with resolved HBV infection who received antiviral prophylaxis, none of them experienced a reactivation of their infection.
The authors said the study had 3 limitations: retrospective observations were limited by patient variability in monitoring HBV; the study had a small sample size; and the study had relatively short media follow-up (23.21 months).
The authors said the study showed that HBV reactivation and hepatitis flare might occur a few months after ruxolitinib treatment in patients with chronic HBV infection who did not take antivirals prophylactically, especially in combination with TSP.
However, it was rare in patients with resolved HBV infection.
Reference
Duan MH, Cao XX, Chang L, Zhou DB. Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms. Hematology. 2021 Dec;26(1):460-464. doi: 10.1080/16078454.2021.1945234.
Higher UTI Risk After Spinal Fusion in Patients With Certain Comorbidities
March 5th 2025A study investigated the incidence of postoperative urinary tract infections (UTIs) in patients undergoing spinal fusion for deformities, finding that patients with more than 12 levels fused had the highest UTI rates.
Read More
Survey Explores Needs of Patients With DMD, BMD Transitioning to Adulthood
February 28th 2025Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), but those who had more siblings reported being more ready to transition to adult life.
Read More
Falls, Balance Issues Signal Higher ICANS Risk in NHL
February 28th 2025Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Read More
Higher UTI Risk After Spinal Fusion in Patients With Certain Comorbidities
March 5th 2025A study investigated the incidence of postoperative urinary tract infections (UTIs) in patients undergoing spinal fusion for deformities, finding that patients with more than 12 levels fused had the highest UTI rates.
Read More
Survey Explores Needs of Patients With DMD, BMD Transitioning to Adulthood
February 28th 2025Activities of daily life, education, and employment were areas of difficulty in the transition to adulthood for patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD), but those who had more siblings reported being more ready to transition to adult life.
Read More
Falls, Balance Issues Signal Higher ICANS Risk in NHL
February 28th 2025Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Read More
2 Commerce Drive
Cranbury, NJ 08512